Bevacizumab [electronic resource] : the first FDA-approved angiogenesis inhibitor in the treatment of non-small cell lung cancer / Tracey Evans.
Material type:
FilmSeries: Henry Stewart talksBiomedical & life sciences collection. Cancer therapy : latest thinking in efficacy and toxicity: Publisher: London : Henry Stewart Talks, 2009Description: 1 online resource (1 streaming video file (54 min.) : color, sound)Subject(s): Angiogenesis Inhibitors -- therapeutic use | Carcinoma, Non-Small-Cell Lung -- drug therapy | Lung Neoplasms -- drug therapy | Neoplasms -- complications | Neoplasms -- therapyOnline resources: Click here to access online | Series Animated audio-visual presentation with synchronized narration.
Title from title frames.
Contents: Lung cancer incidence -- Survival by treatment group -- Selected trials of novel agents + chemotherapy -- Bevacizumab -- Vascular Endothelial Growth Factor (VEGF) -- Principles of angiogenesis -- Bevacizumab in NSCLC: not for everybody -- Randomized phase II trial of Paclitaxel/Carboplatin with/without Bevacizumab in NSCLC -- Hemorrhagic events -- Example of tumor cavitation in lung following treatment with chemotherapy and Bevacizumab -- Patient haracteristics -- Response rates -- Hematologic and non-hematologic toxicity -- Treatment related deaths -- Efficacy by gender and age -- NCCN pactice guidelines in oncology-v.2.2008 -- AVAiL: phase III trial of Bevacizumab + Gemcitabine and Cisplatin in advanced non|squamous cell NSCLC -- Second line therapy for advanced NSCLC: the role of Bevacizumab -- Adjuvant therapy in NSCLC -- Can a broader range of patients be safely treated with Bevacizumab? -- Protocol AVF3744g: BRIDGE trial.
Access restricted to subscribers.
Mode of access: World Wide Web.